Global Roundup: Norway's Cytovation Snags $20 Million in a Series A - read this article along with other careers information, tips and advice on BioSpace
Important clinical milestones are expected in 2022 in the Company's hemato-oncology and immuno-oncology programs. MaaT013, the Company's lead Microbiome Ecosystem Therapy, is ready to enter
Capital increase of 2,333,333 new ordinary shares (corresponding, on an indicative basis, to an amount of approximately €35.0 m1) which may be increased to a maximum of 3,085,831 ordinary new shares